Drugs / EPN-701
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05285787 | Mar 2019 → Apr 2021 | end stage renal failure | Epizon Pharma, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07583745 Comparator | Jul 2026 → Jun 2030 expected | calciphylaxis | Sagar U. Nigwekar, MD, MMSc | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPN-701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07583745 ↗ |
| Route | Oral | “EPN-701 will be administered daily by mouth” NCT07583745 ↗ |